Sustained remission of severe resistant autoimmune neutropenia with Campath‐1H

• Published in: British journal of haematology Vol. 97; no. 2; pp. 306 - 308
• Main Authors: Killick, S. B., Marsh, J. C. W., Hale, G., Waldmann, H., Kelly, S. J., Gordon‐Smith, E. C.
• Format: Journal Article
• Language: English
• Published: Oxford, U.K. and Cambridge, USA Blackwell Science Ltd 01-05-1997; Blackwell
• Subjects: Alemtuzumab; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm - therapeutic use; Autoimmune Diseases - therapy; autoimmune neutropenia; Biological and medical sciences; Campath‐1 antibodies; Campath‐1H; Female; Hematologic and hematopoietic diseases; Humans; Infusions, Intravenous; Leukocyte Count; Medical sciences; Middle Aged; Neutropenia - therapy; Other diseases. Hematologic involvement in other diseases; Human; Case study; Immunopathology; Treatment; Leukopenia; Adult; Autoimmune disease; Remission; Hemopathy; Monoclonal antibody; Neutropenia; Prolonged
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1046/j.1365-2141.1997.612718.x

We report the course of a patient with severe autoimmune neutropenia in whom only transient responses occurred with corticosteroids, antilymphocyte globulin and granulocyte‐colony stimulating factor, and who was resistant to treatment with azathioprine, cyclosporin and intravenous immunoglobulin. A 10 d course of intravenous Campath‐1H monoclonal resulted in a sustained haematological response. The long‐lasting effect of Campath‐1H may be due to its remarkable ability to induce a profound and prolonged peripheral blood T lymphopenia.